-+ 0.00%
-+ 0.00%
-+ 0.00%

United Therapeutics Reports First UThymoKidney Transplant in EXTEND Trial

PUBT·11/20/2026 12:03:10
Diffusion vocale
United Therapeutics Reports First UThymoKidney Transplant in EXTEND Trial
  • United Therapeutics announced the first UThymoKidney transplant in its EXTEND trial for patients with end-stage renal disease, performed at NYU Langone Health.
  • The study evaluates a pig kidney containing thymic tissue intended to reduce organ rejection in patients with limited transplant options.
  • EXTEND is the second clinical trial in the company's xenotransplantation program, which aims to support applications for FDA approval.
  • Results from the first six transplants will be submitted to the FDA before planned expansion to additional centers and a larger study population.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611200700BIZWIRE_USPR_____20261120_BW034515) on November 20, 2026, and is solely responsible for the information contained therein.